

Dosimetry-Guided Radiopharmaceutical Therapy

Preface	9
Glossary	10
List of Symbols	16
Abstract	17
 1. Introduction	18
1.1 Developments in Radiopharmaceutical Therapy	18
1.2 Outline of the Report	20
1.2.1 Introduction to the Outline	20
1.2.2 Fundamental Concepts of Radionuclides	20
1.2.3 Fundamental Concepts in Radiation Dosimetry	20
1.2.4 Radiobiology and Bioeffect Modeling	20
1.2.5 Conceptual Framework for Radiopharmaceutical Therapy Patient Dosimetry	21
1.2.6 Dosimetry-Based Prescriptions	21
1.2.7 Quantification of Activity in Source Regions for Dosimetry	21
1.2.8 Pharmacokinetics	21
1.2.9 Calculation of Absorbed Dose in Target Volumes	21
1.2.10 Implementing Radiopharmaceutical Therapy Treatment-Planning	21
1.2.11 Combination Therapies with Radiopharmaceuticals	21
1.2.12 Prescribing, Recording, and Reporting	21
1.2.13 Future Areas of Study in Radiopharmaceutical Therapy	21
 2. Fundamental Concepts of Radionuclides	22
2.1 Alpha-Particle Decay	22
2.2 Beta-Particle Decay	23
2.2.1 Beta-minus Decay	23
2.2.2 Beta-plus Decay	23
2.2.3 Beta-particle Kinematics	24
2.2.4 Bremsstrahlung X-rays Photons	24
2.3 Electron Capture Decay	25
2.4 Internal Transition and Internal Conversion	25
2.5 Characteristic X-rays and Auger Electrons	25
2.6 Branched Decays	26
2.7 Decay Chains	26
2.8 Mean Energy Emitted per Radioactive Transformation	27
2.9 Radionuclides Suitable for Therapeutic Applications	27
2.10 Sources for Radionuclide Decay-Scheme Data	31
2.11 Example Decay Scheme – ^{123}I (Electron Capture)	31
2.12 Example Decay Scheme – ^{223}Ra (Alpha-Particle Decay)	33
 3. Fundamental Concepts in Radiation Dosimetry	37
3.1 Linear Energy Transfer	37
3.2 Deposition of Energy	37
3.2.1 Energy Deposit	37
3.2.2 Energy Imparted	37
3.2.3 Absorbed Dose	38
3.2.4 Absorbed Dose Rate	38
3.2.5 Mean Absorbed Dose	38

3.3	MIRD Schema for Absorbed Dose Computation	38
3.3.1	Mean Absorbed Dose Rate	38
3.3.2	Mean Absorbed Dose: Time-Dependent Formulation	39
3.3.3	Mean Absorbed Dose: Time-Independent Formulation	39
3.4	Models of Time-Dependent Activity in Source Regions	40
3.4.1	Time-Dependent Activity in Source Regions	40
3.4.2	Time-Dependent Activity From Multicompartment Models of Systemic Biodistribution	40
4.	Radiobiology and Bioeffect Modeling	43
4.1	Radiation Interactions With Tissues	43
4.2	Linear Energy Transfer and Relative Biological Effectiveness	44
4.3	DNA Damage and Repair	48
4.3.1	Radiation-Induced DNA Damage and Repair	48
4.3.2	Additional DNA Damage Mechanisms Unique to Radiopharmaceuticals	48
4.4	Cell Death and Cell Survival Curves	50
4.4.1	Modes of Cell Death	50
4.4.2	Cell Survival Curves	50
4.4.3	Effect of Absorbed Dose Rate on Cell Survival	50
4.5	Bystander Effect	51
4.6	Biological Modifiers of Response	52
4.7	Further Considerations Regarding the Radiobiology of Alpha Particles	54
4.7.1	RBE of Alpha-Particle Emitters	54
4.7.2	Exploiting DNA Repair Pathways to Increase RBE	56
4.7.3	Oncogenesis	58
4.8	Normal Tissue Toxicity Caused by Ionizing Radiation	59
4.8.1	Deterministic Effects	60
4.8.2	Stochastic Effects	62
4.8.3	Teratogenesis (Deterministic and Stochastic)	62
4.9	Bioeffect Modeling in RPT	63
4.9.1	Introduction	63
4.9.2	Absorbed Dose Rate and the LQ Model	63
4.9.3	Biologically Effective Dose	63
4.9.4	Equieffective Dose (EQDX)	66
4.9.5	Standardized Relative Biological Effectiveness—sRBEX	66
4.9.6	Equieffective Dose Versus RBE-Weighted Dose	67
4.9.7	Equivalent Uniform Dose	67
4.9.8	Tumor Control Probability	69
4.9.9	Normal Tissue Complication Probability and Organ Models	69
4.9.10	Cellular and Multicellular Bioeffect Modeling	69
4.9.11	Concluding Remarks	71
5.	Conceptual Framework for RPT Patient Dosimetry	72
5.1	Introduction	72
5.2	RPT Considerations	72
5.2.1	Dosimetry in RPT Compared With Other Radiotherapy Modalities	72
5.2.2	Considerations Regarding the Spatial Distribution in RPT	73
5.2.3	Temporal Considerations in RPT	73
5.3	RPT Region Nomenclature	73
5.3.1	Nomenclature for Characterization of the Source Distribution	76
5.3.2	Nomenclature for Treatment Regions	80
5.3.3	Nomenclature for RARs	81

6.	Dosimetry-Based Prescriptions	84
6.1	Overview	84
6.1.1	Prescribed Absorbed Dose and Equieffective Dose	84
6.1.2	Dose-Response Relationships in RPT	85
6.1.3	Concept of a Therapeutic Window	85
6.1.4	Radionuclide Selection, Absorbed Dose Rate, Treatment Fractionation	87
6.1.5	Reliability of Data Used to Derive Prescriptions	88
6.2	Therapeutic Treatment Regions	89
6.2.1	Tumor Doses Required for Effective Treatment	89
6.2.2	Doses Required for Specific Modalities	89
6.3	Regions at Risk	90
6.3.1	The Dose Delivered to Normal Tissues	90
6.3.2	Maximum Safe Administered Activity	90
7.	Quantification of Activity in Source Regions for Dosimetry	92
7.1	Overview	92
7.2	Emission Imaging of Macroscale-Level SRs	92
7.2.1	In Vivo Nuclear Medicine Imaging Systems	92
7.2.2	Image Reconstruction	93
7.2.3	Image Degrading Factors	94
7.3	Absolute Activity Quantification for Dosimetry	97
7.3.1	Camera Deadtime	97
7.3.2	Image Segmentation	98
7.3.3	Determination of Camera Sensitivity and Calibration Factors	100
7.3.4	Partial Volume Correction	102
7.4	Guidelines for In Vivo Quantitative SPECT and PET Imaging for Dosimetry	102
7.4.1	Overview	102
7.4.2	Imaging Surrogates for Theranostic Dosimetry	104
7.4.3	Imaging of Therapy Radionuclides	109
7.4.4	Gamma Camera Imaging in Alpha-Particle Therapies	116
7.4.5	Summary Table of Imaging Guidelines for Some Common Therapies	119
7.5	Uncertainty in Source Region Activity Estimation	123
7.6	Nonimaging Detection Systems Used for Activity Quantification in Dosimetry	124
7.6.1	Probe-Based Systems	125
7.6.2	Activity Meters	126
8.	Pharmacokinetics	127
8.1	Introduction	127
8.2	Trapezoid Integration	128
8.3	Curve Fitting to Time-Activity Data	128
8.3.1	Estimation of the Time-Integrated Activity Based on Multiple Data Points	128
8.3.2	Estimation of the Time-Integrated Activity Based on a Single Data Point	130
8.4	Compartment Modeling	131
8.5	Summary	132
9.	Calculation of Absorbed Dose	133
9.1	Monte Carlo Radiation Transport Simulation	133
9.1.1	Limitations of MC Simulations	133
9.1.2	Transport Methodologies	134
9.1.3	General Considerations Specific to RPT	134
9.1.4	A Guide to Best Practice	135
9.2	Dose-Point-Kernel Convolution	135
9.2.1	Definitions	135
9.2.2	Charged Particles	137

9.2.3 Uncharged Particles.....	137
9.2.4 Convolution Integral	137
9.2.5 Nonhomogeneous Medium	138
9.2.6 Limitations	140
9.3 Radionuclide S-Coefficients and the MIRD Schema	140
9.3.1 Radionuclide S-Coefficients at the Organ Level.....	141
9.3.2 Radionuclide S-Coefficients at the Suborgan Level	145
9.3.3 Radionuclide S-Coefficients at the Voxel Level.....	147
9.3.4 Radionuclide S-Coefficients at the Cellular Level	149
10. Implementing Radiopharmaceutical Therapy Treatment-Planning	150
10.1 Introduction	150
10.2 Development Pathway for Nonradioactive Agents	150
10.3 Development Pathway for RPT Agents	150
10.4 Recommended Development Pathway for RPT Agents	151
11. Combination Therapies with Radiopharmaceuticals.....	153
11.1 Introduction	153
11.2 Sequential Treatments.....	154
11.3 Qualitative Combinations	154
11.4 Quantitative Combinations.....	156
11.4.1 RPT—EBRT Combinations	156
11.4.2 RPT-RPT Combinations.....	158
12. Prescribing, Recording and Reporting	164
12.1 ICRU Reporting Levels.....	164
12.2 Dose Prescription in RPT	165
12.3 Reporting in RPT	165
12.3.1 Recommendations for Reporting at Level 1	166
12.3.2 Recommendations for Reporting at Level 2	166
12.3.3 Recommendations for Reporting at Level 3	166
12.3.4 Motivation and Rationale for the Different Levels.....	167
13. Future Areas of Study in Radiopharmaceutical Therapy	171
Appendix A: Clinical Examples.....	172
A.1 ^{131}I NaI Treatment of Benign Thyroid Disease	172
A.1.1 General Considerations	172
A.1.2 Dosimetry Methods	172
A.1.3 Report Summary	173
A.2 Treatment of Neuroendocrine Tumors Using ^{177}Lu -DOTATATE	174
A.2.1 General Considerations	174
A.2.2 Dosimetry Methods	174
A.2.3 Report Summary	176
A.3 ^{90}Y Radioembolization.....	177
A.3.1 General Considerations	177
A.3.2 Dosimetry Methods	177
A.3.3 Report Summary	183
A.4 Treatment of Hormone-Sensitive Prostate Cancer With ^{177}Lu -PSMA-617	185
A.4.1 General Considerations	185
A.4.2 Dosimetry Methods	186
A.4.3 Report Summary	187
References	189